CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended		50 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Revenue
Diagnostic Testing Service	$ 120,488	$ 219,972	$ 289,718	$ 272,685	$ 765,120
Product Sales	205,590	3,125	219,030	5,125	226,970
Total Revenue	326,078	223,097	508,748	277,810	992,090
Cost of Revenue
Diagnostic Testing Service	2,356	17,788	49,955	20,985	85,700
Product Sales	219,804	0	238,669	0	243,833
Total Cost of Revenue	222,160	17,788	288,624	20,985	329,533
Loss on Reduction of Inventory to LCM	0	0	0	23,807	121,910
Gross Profit	103,918	205,309	220,124	233,018	540,647
Selling expenses	319,390	123,832	591,965	194,267	1,231,841
Research and Development expenses	189,955	543,081	410,147	961,071	3,967,533
General and Administrative expenses	2,177,920	704,208	3,742,792	1,305,660	9,565,126
Total operating expenses	2,687,265	1,371,121	4,744,904	2,460,998	14,764,500
Operating Loss	(2,583,347)	(1,165,812)	(4,524,780)	(2,227,980)	(14,223,853)
Interest Income	0	310	0	1,173	6,588
Interest Expense	352	2,446	359	4,060	39,530
Net Loss before Income Taxes	(2,583,699)	(1,167,948)	(4,525,139)	(2,230,867)	(14,256,795)
Income Taxes	0	0	0	0	250
Net Loss	$ (2,583,699)	$ (1,167,948)	$ (4,525,139)	$ (2,230,867)	$ (14,257,045)
Loss per common share - basic and diluted (in dollars per share)	$ (0.17)	$ (0.10)	$ (0.32)	$ (0.20)	$ (1.63)
Weighted average shares outstanding, basic & diluted (in shares)	14,808,728	11,256,867	14,120,962	11,256,867	8,722,843